At Axol Bioscience, we support your pursuit of more effective, safer therapies. Like you, we believe that having more human-relevant disease models will expand scientific knowledge and de-risk drug development. We use human iPSCs to achieve this and have been doing so since 2006. We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models. We have a special focus on neurodegenerative diseases like Alzheimer’s disease as well as cardiotoxicity to promote drug safety. When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier-stage modeling and safety testing and later-stage efficacy evaluation and improved patient selection. With these data comes better insights, helping you de-risk projects, reduce costs, and save time during drug development.